CTC
CLDX icon

Central Trust Company’s Celldex Therapeutics CLDX Stock Holding History

Central Trust Company’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-22
Closed -$9K – 1191
2015
Q1 		$9K Hold
22
– – ﹤0.01% 997
2014
Q4 		$6K Hold
22
– – ﹤0.01% 1058
2014
Q3 		$4K Hold
22
– – ﹤0.01% 1093
2014
Q2 		$5K Hold
22
– – ﹤0.01% 1052
2014
Q1 		$6K Buy
22
+15
+214% +$5.74K ﹤0.01% 1027
2013
Q4 		$2K Hold
7
– – ﹤0.01% 1090
2013
Q3 		$4K Buy
+7
New +$2.4K ﹤0.01% 1065

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Central Trust Company's CLDX Position: Q2 2015 in Review

Central Trust Company sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 22 shares — an estimated $9K sold.

Central Trust Company first reported a position in CLDX in Q3 2013 and held it in 7 quarters. The position peaked at $9K in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

  • Central Trust Company reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Central Trust Company sold 22 Celldex Therapeutics shares in Q2 2015, an estimated $9K.
  • Central Trust Company first reported a position in Celldex Therapeutics in Q3 2013 and held it in 7 quarters.
  • Central Trust Company's Celldex Therapeutics position peaked at $9K in Q1 2015.
  • 186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on Central Trust Company's 13F filing for Q2 2015, filed 28 Jul 2015.